Literature DB >> 22993476

Recurrent bilateral subconjunctival hemorrhage as an initial presentation of multiple myeloma.

Anthony F Felipe1, Jennifer M Nottage, Christopher J Rapuano.   

Abstract

Entities:  

Year:  2012        PMID: 22993476      PMCID: PMC3441025          DOI: 10.4103/0974-620X.99384

Source DB:  PubMed          Journal:  Oman J Ophthalmol        ISSN: 0974-620X


× No keyword cloud information.
Multiple myeloma can be an underlying cause of recurrent subconjunctival hemorrhage. We report one such case of multiple myeloma that presented with repeated subconjunctival hemorrhage in both eyes. A 48-year-old previously healthy Caucasian male consulted our clinic due to recurrent redness in both eyes (OU). He had experienced similar episodes for the past 7 years and that the redness would last for 1-2 weeks and slowly resolve without treatment. He denied blurred vision, pain, itching, lid matting, or discharge during episodes as well as previous trauma, anticoagulant use, Valsalva maneuvers, or coughing. The patient had good health otherwise and was not on any systemic medications. Review of systems was essentially normal except for occasional numbness in both feet. His best-corrected visual acuity was 20/20 OU. Intraocular pressures were within normal limits. Mild inferior eyelid retraction OU was noted but there was no proptosis. Slit-lamp examination demonstrated bilateral subconjunctival hemorrhage inferiorly with mild chemosis OU [Figure 1]. Dilated fundus examination was unremarkable OU. He was referred to the Oculoplastics Service for further evaluation of eyelid retraction and to his medical doctor for a systemic work-up.
Figure 1

Subconjunctival hemorrhage more pronounced inferiorly (a) right eye (b) left eye

Subconjunctival hemorrhage more pronounced inferiorly (a) right eye (b) left eye His systemic work-up was essentially normal except for elevated total protein in the blood. He underwent serum immunolectrophoresis that showed monoclonal gammopathy. Subsequent bone marrow aspiration biopsy revealed plasmacytosis consistent with multiple myeloma. He was referred to an oncologist for chemotherapy.

Discussion

The ocular manifestations in multiple myeloma have been well described.[1] Corneal and conjunctival involvement are usually in the form of fine crystals deposited at different levels of the cornea and bulbar conjunctiva respectively.[23] Amyloidosis occurs in 5% to 15% of patients with multiple myeloma.[1] Conjunctival involvement in amyloidosis associated with myeloma presents as subconjunctival hemorrhage presumably due to amyloid deposits in the walls of small vessels causing fragility.[45] Despite the general belief that subconjunctival hemorrhages are benign, multiple myeloma with amyloidosis should be suspected in patients with recurrent subconjunctival hemorrhage that occur either spontaneously or following minimal trauma or Valsalva maneuver. Table 1 lists other possible causes of recurrent subconjunctival hemorrhage. Although we did not observe any obvious amyloid deposits in our patient's eyes, a subclinical entity is presumed to be involved leading to fragile conjunctival vessels. We decided not to perform a conjunctival biopsy since the patient was already diagnosed with multiple myeloma on his follow-up visit and there was no therapeutic indication to perform such a procedure. At his follow-up appointment, no further episodes of subconjunctival hemorrhage and conjunctival chemosis occurred. The patient had no other complaints aside from paresthesias of both feet and the systemic investigation that resulted in the diagnosis of myeloma was prompted entirely by the ocular manifestations.
Table 1

Possible causes of recurrent subconjunctival hemorrhage

Possible causes of recurrent subconjunctival hemorrhage In conclusion, this case demonstrates that multiple myeloma may present clinically as recurrent subconjunctival hemorrhages. Although considered benign, this ophthalmic finding may be the initial presentation of a more serious disease entity, such as an underlying neoplastic condition. Systemic work-up should therefore be performed in cases of frequent subconjunctival hemorrhage without known pathological causes.
  5 in total

1.  Corneal crystals in multiple myeloma.

Authors:  S B ARONSON; R SHAW
Journal:  AMA Arch Ophthalmol       Date:  1959-04

2.  Recurrent subconjunctival and periorbital haemorrhage as the first presentation of systemic AL amyloidosis secondary to myeloma.

Authors:  G T Higgins; A Olujohungbe; G Kyle
Journal:  Eye (Lond)       Date:  2006-04       Impact factor: 3.775

3.  Primary localized conjunctival amyloidosis presenting with recurrence of subconjunctival hemorrhage.

Authors:  H M Lee; J Naor; D DeAngelis; D S Rootman
Journal:  Am J Ophthalmol       Date:  2000-02       Impact factor: 5.258

4.  Corneal and conjunctival changes in dysproteinemia.

Authors:  R M Pinkerton; D M Robertson
Journal:  Invest Ophthalmol       Date:  1969-08

5.  Multiple myeloma and its ocular manifestations.

Authors:  A J Knapp; S Gartner; P Henkind
Journal:  Surv Ophthalmol       Date:  1987 Mar-Apr       Impact factor: 6.048

  5 in total
  5 in total

1.  Endogenous Panophthalmitis in a case of Multiple Myeloma and Diabetes Mellitus.

Authors:  Madhurima K Nayak; Neha Singh
Journal:  J Clin Diagn Res       Date:  2016-07-01

2.  Incidence of Non-Traumatic Subconjunctival Hemorrhage in an Indian Rural Population.

Authors:  Rajesh Subhash Joshi; Rahul Ramchandra Bandgar
Journal:  Clin Ophthalmol       Date:  2021-01-15

3.  Subconjunctival hemorrhage: risk factors and potential indicators.

Authors:  Bercin Tarlan; Hayyam Kiratli
Journal:  Clin Ophthalmol       Date:  2013-06-12

4.  Cloudy corneas as an initial presentation of multiple myeloma.

Authors:  Priyanka Sharma; Haifa A Madi; Richard Bonshek; Stephen J Morgan
Journal:  Clin Ophthalmol       Date:  2014-04-28

Review 5.  Corneal Opacity Leading to Multiple Myeloma Diagnosis: A Case Report and Literature Review.

Authors:  Naiyang Li; Zhe Zhu; Gengrong Yi; Sheng Li; Xiaotong Han
Journal:  Am J Case Rep       Date:  2018-04-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.